

Genetic modification of the relationship between phosphorylated tau and neurodegeneration

Timothy J. Hohman^{*}, Mary Ellen I. Koran, Tricia A. Thornton-Wells, for the Alzheimer's Disease Neuroimaging Initiative¹

The Center for Human Genetics Research, Department of Molecular Physiology & Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA

Abstract

Background: A subset of individuals present at autopsy with the pathologic features of Alzheimer's disease having never manifest the clinical symptoms. We sought to identify genetic factors that modify the relationship between phosphorylated tau (PTau) and dilation of the lateral inferior ventricles.

Methods: We used data from 700 subjects enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI). A genome-wide association study approach was used to identify PTau \times single nucleotide polymorphism (SNP) interactions. Variance explained by these interactions was quantified using hierarchical linear regression.

Results: Five SNP \times PTau interactions passed a Bonferroni correction, one of which (rs4728029, *POT1*, 2.6% of variance) was consistent across ADNI-1 and ADNI-2/GO subjects. This interaction also showed a trend-level association with memory performance and levels of interleukin-6 receptor.

Conclusions: Our results suggest that rs4728029 modifies the relationship between PTau and both ventricular dilation and cognition, perhaps through an altered neuroinflammatory response.

© 2014 The Alzheimer's Association. All rights reserved.

Keywords:

Alzheimer's disease; Phosphorylated tau; Ventricular volume; MRI; CSF; Memory; GWAS; Genetic interactions; Imaging genetics; Quantitative traits; Plasma

1. Introduction

The pathologic cascade in Alzheimer's disease (AD) has been widely debated. Some suggest that tauopathies play a causal role and initiate the disease process when they arise early in life [1], whereas others posit that amyloid pathology plays a causal role arising through an independent disease process, perhaps after early tauopathies appear, and ultimately leading to an acceleration of the disease process

[2,3]. Emerging out of this literature is evidence that a subset of individuals present at autopsy with tauopathies and amyloid plaques having never shown clinical symptoms of AD during their lifetime [4–6]. Some of this work has suggested that asymptomatic individuals show acute differences in brain activity [7] and longitudinal hypertrophy in hippocampal and cortical cell bodies that may act as a potential mechanism of resilience [6]. Moreover, risk for AD pathology in asymptomatic individuals is much higher in those with a family history of AD than in those without a family history, suggesting that genetic factors may play an important role in the presence and response to AD pathology [8]. Advances in biomarker detection have led to validated measures that can be used to approximate the pathologic processes of AD in vivo including amyloid deposition imaged using positron emission tomography (PET) and levels of A β 42, tau, and phosphorylated tau (PTau) in cerebrospinal fluid (CSF). PET and CSF biomarkers show a strong relationship to each

¹Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.ucla.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

^{*}Corresponding author. Tel.: +1-615-343-0396; Fax: 615-875-2727.

E-mail address: Timothyjhohman@gmail.com

other [9–11], and both predict risk for AD [11]. The availability of genome-wide association study (GWAS) data has led to the identification of a wide array of genetic risk factors for AD [12,13] and associations with AD biomarkers [14–18]. Yet, no study to date has leveraged the availability of these two rich data sources to investigate individual predictors of cognitive resilience seemingly present in asymptomatic individuals.

We sought to identify genetic variants that modify the relationship between biomarkers of tau pathology and a magnetic resonance imaging (MRI) measure of disease progression—lateral ventricle dilation. The lateral ventricles have shown a strong relationship to AD onset and progression [19,20], and measures of ventricular dilation have been successfully applied as quantitative endophenotypes in genetic interaction analyses previously [21]. We approached this research by first characterizing the relationship between tau CSF measures and ventricular volume. Next, we performed a tau-gene interaction analysis to test whether genetic variants modified the relationship between pathology and atrophy. Finally, in post hoc analyses, we tested whether observed tau-gene interactions were associated with cognitive performance or neuroinflammatory cytokine levels.

2. Subjects and methods

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). The ADNI was launched in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and nonprofit organizations, as a \$60 million, 5-year, public-private partnership. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessments can be combined to measure the progression of mild cognitive impairment (MCI) and early AD. Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials.

The principal investigator of this initiative is Michael W. Weiner, MD, VA Medical Center and University of California, San Francisco. ADNI is the result of efforts of many coinvestigators from a broad range of academic institutions and private corporations, and subjects have been recruited from more than 50 sites across the United States and Canada. The initial goal of ADNI was to recruit 800 adults, aged 55 to 90 years, to participate in the research, approximately 200 cognitively normal older individuals to be followed for 3 years, 400 people with MCI to be followed for 3 years, and 200 people with early AD to be followed for 2 years. For up-to-date information, see www.adni-info.org.

2.1. Subjects

Participants were enrolled based on criteria outlined in the ADNI protocol (<http://www.adni-info.org/Scientists/AboutADNI.aspx>). Participants genotyped in both ADNI-1 and ADNI-2/GO protocols were included. To avoid spurious genetic effects due to population stratification, only Caucasian participants were used in all analyses. Demographic data are presented in [Table 1](#).

2.2. Genotyping

In ADNI-1, genotyping was performed using the Illumina Infinium Human610-Quad BeadChip (Illumina, Inc., San Diego, CA). In ADNI-2/GO, genotyping was performed on the Illumina OmniQuad array. After quality control (QC) procedures using PLINK (<http://pngu.mgh.harvard.edu/purcell/plink>) [22], 256,790 single nucleotide polymorphisms (SNPs) remained for data analysis ([Appendix](#)).

2.3. Quantification of ventricular dilation

All volumetric data from 1.5-T MRI scans in ADNI were used in our analyses [23,24]. We used the volume of the left inferior lateral ventricle as our primary outcome measurement, given its previous association with neurofibrillary tangle pathology [25], and included a measurement of intracranial volume (ICV) as a covariate in all volume analyses. Both were defined in FreeSurfer (<https://surfer.nmr.mgh.harvard.edu>) [26–30]. Slopes of change in left ventricular volume over time were calculated in SAS 9.3 (SAS Institute Inc, Cary, NC, USA) using mixed model regression (PROC MIXED) to leverage the longitudinal data. In the mixed model regression, time was modeled based on days from baseline for each subject. This was then rescaled so that slopes would represent annual change (days from baseline/365.25). Details on the longitudinal data are presented in [Table 1](#). For additional technical details, see [Appendix](#).

2.4. Statistical analyses: relationship between tau and brain volume

Biomarker quantification in ADNI was performed previously [11,31]. To test the relationship between PTau and ventricular dilation, we performed a univariate general linear model regression analysis using IBM SPSS v.20 (<http://www-01.ibm.com/software/analytics/spss/>), with the slope of change in left ventricular volume set as the quantitative outcome measure. Predictors in the model included baseline age, baseline ICV, gender, years of education, diagnosis at baseline, and PTau. To maximize our power to identify genetic effects, we chose to exclude *APOE* genotype as a covariate. However, we also wanted to ensure that observed effects were not simply carrying signal related to *APOE* genotype, so we implemented an

Table 1
Demographic information

Variable	Baseline clinical diagnosis*		
	Normal control	Mild cognitive impairment	Alzheimer's disease
ADNI-1 data set			
Number of patients	102	180	92
Number of APOE ε4 carriers	24	99	64
Number of females	48	60	38
Mean baseline age ± SD	75.75 ± 4.99	74.58 ± 7.61	75.01 ± 7.97
Mean years of education ± SD	15.92 ± 2.71	15.76 ± 3.01	15.25 ± 3.22
Mean number of visits ± SD	5.09 ± 1.42	5.17 ± 1.74	3.34 ± 0.89
Mean interval in days ± SD	1320 ± 549	1032 ± 542	585 ± 252
Phosphorylated tau ± SD (pg/mL)	25.77 ± 15.23	35.11 ± 17.09	41.47 ± 18.48
ADNI-2/GO data set			
Number of patients	95	208	23
Number of APOE ε4 carriers	22	90	15
Number of females	46	92	9
Mean baseline age ± SD	74.66 ± 5.63	71.39 ± 7.32	74.96 ± 10.67
Mean years of education ± SD	16.47 ± 2.56	15.96 ± 2.69	15.48 ± 2.76
Mean number of visits ± SD	3.55 ± 1.03	3.94 ± 0.89	3.35 ± 0.93
Mean interval in days ± SD	366 ± 150	470 ± 202	313 ± 143
Phosphorylated tau ± SD (pg/mL)	21.42 ± 7.94	24.76 ± 12.42	35.46 ± 12.86
Combined data set			
Number of patients	197	388	115
Number of APOE ε4 carriers	45	189	79
Number of females	94	152	47
Mean baseline age ± SD	75.22 ± 5.32	72.86 ± 7.62	75.00 ± 8.53
Mean years of education ± SD	16.19 ± 2.65	15.87 ± 2.84	15.30 ± 3.13
Mean number of visits ± SD	4.35 ± 1.46	4.51 ± 1.48	3.34 ± 0.90
Mean interval in days ± SD	860 ± 628.06	731 ± 486	530 ± 258
Phosphorylated tau ± SD (pg/mL)	23.68 ± 12.43	29.56 ± 15.63	40.26 ± 17.61

Abbreviations: ADNI, Alzheimer's Disease Neuroimaging Initiative; SD, standard deviation.

*Normal control subjects had a Mini-Mental Status Examination (MMSE) score between 24 and 30, a Clinical Dementia Rating (CDR) score of 0, and were not depressed (Geriatric Depression Scale score <6). Mild cognitive impairment subjects had an MMSE score between 24 and 30, objective memory impairment, subjective memory impairment, and a CDR score of 0.5. Alzheimer's disease subjects met clinical criteria for dementia, had an MMSE score between 20 and 26, and had CDR score of 0.5 or 1.

approach taken in previous research [32], in which we performed post hoc hierarchical linear regression including APOE genotype to calculate variance explained by observed genetic interactions above and beyond variance explained by APOE. This approach aimed to balance statistical power with interpretability.

2.5. Statistical analyses: gene-PTau interaction analysis

Genetic interaction analyses were performed in PLINK using the `-linear` command, with slopes of ventricular volume set as the outcome variable. An additive model was used for all genotypes (0, 1, and 2) with the same covariates entered previously and the addition of the SNP predictor ($Y = \beta_0 + \beta_1$ baseline age + β_2 baseline ICV + β_3 gender + β_4 education + β_5 Dx + β_6 PTau + β_7 SNP + β_8 SNP × PTau). Our term of interest was a PTau × SNP interaction term, which we used to identify SNPs that modified the relationship between ventricular volume and CSF PTau. A correction for multiple comparisons using the Bonferroni procedure (256,790 total tests) was applied to the PTau × SNP interaction term. Finally, all significant in-

teractions were stratified across the ADNI-1 and ADNI-2/GO data sources to verify the consistency of the observed effect.

2.6. Hierarchical linear regression to identify variance explained

To place our observed SNP interaction effects in the context of known predictors of brain volume including APOE, we used hierarchical linear regression to calculate the change in R^2 when adding in the SNP main effect and after adding in the SNP × PTau interaction term. We report the variance explained by the final block in this model, which is the variance explained by the SNP × PTau interaction term. Population covariates were calculated using Structure (<http://pritchardlab.stanford.edu/structure.html>) [33]. For additional details, see Appendix.

2.7. Post hoc statistical analyses

Post hoc analyses were performed using cognitive [34,35] and plasma-based proteomic markers from ADNI (see Appendix for technical details). Predictors

included baseline age, gender, years of education, diagnostic group, *APOE*, PTau, SNP, and the SNP \times PTau interaction term.

3. Results

3.1. Relationship between PTau and brain volume

As expected, we observed a relationship between levels of PTau in CSF and ventricular volume when controlling for known predictors ($t = 3.08$; $P = .002$). All predictors except gender and education were associated with ventricular volume. We chose to leave all the covariates in our subsequent statistical models. The overall regression model explained 34% of variance in ventricular dilation.

3.2. PTau-gene interaction

Results are presented in Table 2. Five SNP-PTau interactions remained significant after correcting for multiple comparisons. SNPs were annotated using the Illumina annotation file. Two SNPs (rs10973683 and rs7859035) were annotated to the *SHB* gene, one SNP (rs10514128) was annotated to the *TBCA* gene, one SNP (rs2273704) was annotated to the *EML1* gene, and one SNP (rs4728029) was annotated to the *POT1* gene. When stratifying across the data sets, only the rs4728029-PTau interaction result remained significant in both ADNI-1 and ADNI-2/GO. Therefore, we focused all post hoc analyses on this SNP-PTau interaction. For the rs4728029 SNP, approximately 20% of participants were homozygous carriers of the A allele ($n = 141$) and 30% were homozygous carriers of the G allele ($n = 217$). This distribution was reflected in both the ADNI-1 and ADNI-2/GO cohorts. PTau was related to ventricular dilation, and this effect was strongly amplified in homozygous carriers of the rs4728029 A allele (Fig. 1).

3.3. Hierarchical linear regression result

Results are presented in Table 3. Our statistical model without *APOE*, rs4728029, or the rs4728029 \times PTau interaction term explained 34% of variance in ventricular dilation. *APOE* genotype explained an additional 0.9% of variance. A weak, although significant, relationship between

APOE and longitudinal change in volume is consistent with previous findings in which *APOE* was not related to volume loss in normal controls or MCI and only showed a moderate effect in AD [36]. The main effect of rs4728029 explained an additional 0.1% of variance. Finally, the rs4728029 \times PTau interaction term explained an additional 2.5% of variance.

3.4. Post hoc statistical analyses

3.4.1. Cognitive performance

In the executive function analysis, the rs4728029 \times PTau interaction term did not reach statistical significance. However, in the memory analysis, the rs4728029 \times PTau interaction term was statistically significant ($t = -2.22$; $P = .026$). This effect did not survive correction for multiple comparisons. PTau was related to poor memory performance, and the effect was amplified in homozygous carriers of the rs4728029 A allele (Fig. 2).

3.4.2. Neuroinflammatory cytokine analysis

Proteomic data were only available from ADNI-1. There was no association between the rs4728029 \times PTau interaction term and any of the neuroinflammatory cytokines. We also ran the model with rs4728029 recessively coded as A/A = 1 and all other genotypes = 0, and in this model, the interaction term approached nominal statistical significance ($t = 1.950$; $P = .052$). This effect did not survive correction for multiple comparisons. PTau was related to lower levels of IL-6R but only in A/A homozygotes (Fig. 3).

4. Discussion

The present project has replicated the relationship previously observed between CSF levels of phosphorylated tau and neurodegeneration [37,38]. We have also identified a novel genetic-PTau interaction by which variation in a SNP annotated to *POT1* modified the observed relationship between PTau and ventricular dilation. This interaction remained significant after correcting for multiple comparisons. Finally, we demonstrated that this SNP \times PTau interaction was nominally associated with memory performance.

Table 2
PTau-gene interaction analysis

SNP \times SNP interactions	ADNI-1 data set		ADNI-2/GO data set		Combined data sets		FWE*
	t	P value	t	P value	t	P value	
<i>POT1</i> (rs4728029) \times PTau	4.26	.00003	2.33	.020	5.36	1.11×10^{-7}	.045
<i>SHB</i> (rs1097368) \times PTau	4.10	.00005	1.40	.164	5.44	7.26×10^{-8}	.019
<i>SHB</i> (rs7859035) \times PTau	4.41	.00001	1.33	.184	5.44	7.60×10^{-8}	.019
<i>TBCA</i> (rs10514128) \times PTau	4.25	.00003	1.52	.130	5.39	9.52×10^{-8}	.024
<i>EML1</i> (rs2273704) \times PTau	4.39	.00001	1.23	.220	2.28	1.74×10^{-7}	.029

Abbreviations: PTau, phosphorylated tau; SNP, single nucleotide polymorphism; ADNI, Alzheimer's Disease Neuroimaging Initiative.

*FWE— P value when correcting for total number of comparisons using the Bonferroni procedure.




Fig. 1. *POT1* (rs4728029) modifies the relationship between phosphorylated tau (PTau) and lateral inferior ventricle dilation. The y-axis represents annual change in ventricular volume in cubic millimeter. The x-axis represents cerebrospinal fluid (CSF) P-Tau in pg/mL. Points and lines are color coded by rs4728029 genotype. The R^2 linear for A/A carriers is 0.17, for A/G or G/A carriers it is 0.06, and for G/G carrier it is 0.02. ICV, intracranial volume.

4.1. Genetic modification of P-Tau-related neurodegeneration

Across diagnostic categories, increased levels of P-Tau were related to increased ventricular dilation, although this effect was most pronounced in the MCI diagnostic group (the diagnosis-by-P-Tau interaction was not statistically significant; $P = .16$). The genetic modification of this effect highlighted a subgroup of individuals who showed the strongest relationship between P-Tau and neurodegeneration. This effect was not driven by a low frequency of homozygous minor allele carriers as A/A allele carriers of rs4728029 made up 20% of the total sample (146 subjects), and the interaction effect was present when stratifying across the two independent data sources. Importantly, although the rs4728029 SNP did not show a strong main effect on ventricular dilation, the P-Tau interaction explained 2.4% of variance above and

beyond known predictors of neurodegeneration including the *APOE* $\epsilon 4$ genotype. This highlights how the inclusion of genetic interaction effects, particularly when focusing on common variants, can improve prediction models and provide some suggestions as to the mechanisms of risk and resilience as outlined in the following.

The correlative nature of the present analyses precludes our ability to make definitive statements about the mechanisms of the observed interaction; however, some possible hints can be garnered from the rich data sources now available on SNP function. Rs4728029 is an intergenic SNP upstream from protection of telomeres 1 (*POT1*) and downstream from the metabotropic glutamate receptor 8 (*GRM8*). This SNP modifies three regulatory motifs and has the strongest effect on the CEBPB_known2 motif (Transfac M00201) [39]. In the case of this motif, the A allele of rs4728029 is associated with strong decrease in regulatory action, suggesting that the A allele in the present analyses may be associated with lower levels of *POT1*. Previous research has demonstrated that *POT1* expression is related to telomere length, with lower levels of *POT1* expression showing a relationship to shorter telomeres [40], and the gene product of *POT1* has demonstrated a similar relationship to telomere length [41]. Interestingly, the length of telomeres has also been associated with AD status in previous research [42]. AD patients had shorter telomeres in T cells than controls, and T-cell telomere length was inversely correlated with a serum marker of neuroinflammation. In post hoc analyses, we further investigated these possibilities by looking for similar *POT1* modification of the relationship between P-Tau and both cognitive performance and levels of neuroinflammatory cytokines in serum.

4.2. Post hoc analyses: cognitive performance and neuroinflammation

Beyond the increased variance explained in ventricular dilation in our primary analyses, our post hoc analyses suggested that the *POT1* \times P-Tau interaction nominally predicts cognitive performance. The rs4728029 SNP modified the relationship between P-Tau and memory performance,

Table 3
Post hoc hierarchical linear regression result

Model	R	R^2	Adj. R^2	Change statistics				
				R^2 change	F change	df1	df2	Sig. F change (P value)
1*	0.589	0.347	0.341	0.347	31.35	6	693	4.33×10^{-6}
2 [†]	0.594	0.353	0.346	0.006	6.27	1	692	.013
3 [‡]	0.597	0.356	0.347	0.004	1.28	3	690	.282
4 [§]	0.598	0.357	0.347	0.001	1.10	1	689	.296
5 [¶]	0.618	0.382	0.371	0.025	27.67	1	688	1.92×10^{-7}

Abbreviations: Adj, adjusted; Sig, significant.

*Predictors: constant, intracranial volume (ICV), phosphorylated tau, age, education, diagnosis, and gender.

[†]Predictors: constant, ICV, phosphorylated tau, age, education, diagnosis, gender, and *APOE*.

[‡]Predictors: constant, ICV, phosphorylated tau, age, education, diagnosis, gender, *APOE*, and eigenvectors 1, 2, and 3.

[§]Predictors: constant, ICV, phosphorylated tau, age, education, diagnosis, gender, *APOE*, eigenvectors 1, 2, and 3, and rs4728029.

[¶]Predictors: constant, ICV, phosphorylated tau, age, education, diagnosis, gender, *APOE*, eigenvectors 1, 2, and 3, rs4728029, and rs4728029 \times P-Tau.




Fig. 2. *POT1* (rs4728029) modifies relationship between PTau and baseline memory performance. The y-axis represents baseline memory performance. The x-axis represents cerebrospinal fluid (CSF) phosphorylated tau in pg/mL. Points and lines are color coded by the rs4728029 genotype. The R^2 linear for A/A carriers is 0.15, for A/G or G/A it is 0.141, and for G/G it is 0.167.

although it did not have an effect on executive function performance. If such an effect is indeed driven by the ventricular dilation observed in our primary analysis, then it is not surprising that the effect is present in relation to memory rather than executive function, particularly given the crucial memory structures that surround the lateral inferior ventricles including the hippocampus. Moreover, the observed interaction was consistent with our primary finding as A/A allele carriers showed both more dilation in the inferior lateral ventricle in relation to PTau load and poorer memory performance at baseline in relation to PTau. These two factors are, of course, highly correlated (Pearson's $r = -0.55$) and, for that reason, should not be interpreted as independent signals as both are likely related to a single underlying factor. In both cases, PTau was related to dilation and memory performance in all genotype subgroups but showed the strongest relationship in the A/A group. Given the relationship between *POT1* and neuroinflammatory cytokines previously mentioned [42] and the relationship between neuroinflammation and brain volume [43], we chose to investigate whether our observed effect may be driven by such a neuroinflammatory response.

Previous research has demonstrated a relationship between telomere length and tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), and IL-1 [42,44]. For this reason, we chose to focus on the TNF- α and IL cytokines available in our data set. We were underpowered to look for such gene-biomarker interactions in relation to cytokines (only available in a subsample of ADNI-1 participants), so our results should be interpreted with caution. We were able to observe a trend gene \times PTau interaction in line with our cognitive and brain volume findings as A/A allele




Fig. 3. *POT1* (rs4728029) modifies relationship between PTau and interleukin-6 receptor. The y-axis represents baseline plasma interleukin-6 receptor levels in ng/mL. The x-axis represents cerebrospinal fluid (CSF) phosphorylated tau levels in pg/mL. Points and lines are color coded by the rs4728029 genotype. The R^2 linear for A/A carriers is 0.062, for G/A or A/G carriers it is 0.0004, and for G/G carriers it is 0.0005.

carriers of rs4728029 showed lower levels of the IL-6 receptor (IL-6R) in relation to increased levels of PTau. IL-6R has previously been suggested to be an anti-inflammatory marker [45], and indeed, the association observed in this post hoc analysis suggests that in persons with lower levels of this anti-inflammatory marker (and possibly higher neuroinflammation), PTau leads to even higher levels of neurodegeneration. Soluble IL-6R appears to play a role in a large number of both pro- and anti-inflammatory activities mediated by IL-6 [46], and these post hoc results must be interpreted within the many actions of the IL-6/IL-6R complex. The present results suggest that future work clarifying the relationship between PTau load, neuroinflammation, and neurodegeneration is warranted.

4.3. Previous GWAS of CSF markers and resilience in ADNI

Previous GWAS analyses have looked for single marker predictors of tau and PTau levels in CSF using data from ADNI. The earliest studies highlighted strong single marker effects in and around the *APOE* gene [18]. Although we did not use PTau as our outcome, we did verify that *APOE* was strongly associated with PTau ($P = 1.9 \times 10^{-11}$). As highlighted in our hierarchical model, the effect of *APOE* on left inferior lateral ventricle (LILV) slopes was more modest, particularly when including PTau in the prediction model ($P = .013$). This is consistent with the modest predictive power of *APOE* in relation to longitudinal change in bilateral hippocampal volume and ventricular volume reported previously [36,47]. An additional GWAS reported a strong association between a SNP within *APOE* and a variety of baseline volume endophenotypes including the right

hippocampus [48]. This suggests that future interaction analyses using a variety of smaller regions of interest may be warranted.

The most comprehensive GWAS of CSF biomarkers to date included data from ADNI and four other data sets [15] and reported a strong relationship between signals on chromosome 19 and biomarker levels. Interestingly, they also highlighted particular signals within the *APOE* region that are related to tau pathology independent of A β 42 pathology or clinical status. In the present manuscript, the strong relationship between PTau and *APOE*, along with the moderate association between *APOE* and ventricular volume, might explain why the strongest gene interaction effects identified do not cluster around the *APOE* signal. Moreover, this key difference highlights the strength of gene-biomarker interactions in identifying novel candidates for future analyses.

In addition, previous work by Cruchaga et al. [14] demonstrated that genetic variation associated with CSF biomarker levels can meaningfully predict disease progression. Taken together, the results of the present manuscript and both Cruchaga et al. manuscripts suggest that genetic risk factors must be considered at all stages of the AD cascade to fully elucidate the genetic etiology of late-onset AD (LOAD). Genetic variants may increase susceptibility to the primary pathologies of LOAD, to neurodegeneration in the presence of a given pathology as presented in this manuscript, or even to cognitive decline in the presence of neurodegeneration (as reported most recently by Mukherjee et al. [49]).

4.4. Strengths and weaknesses

The present manuscript presents a novel genetic interaction approach making use of MRI, CSF, and genotyping data. Combining the two independent data sources allowed us to maximize our power to detect genetic effects, and the stratified post hoc analysis provides support for the consistency of the observed effect. The lack of consistency for some of the SNP interactions may be due to differences in the ADNI-1 and ADNI-2/GO protocols. For example, the longitudinal follow-up scans were slightly more frequent in ADNI-2/GO (approximately every 3 months vs. approximately every 6 months in ADNI-1) but covered a shorter period of time. Certainly, this longer follow-up interval in ADNI-1 could explain the cohort differences we observe, but other differences such as the distribution of diagnostic categories in the two cohorts cannot be ruled out.

In addition, it is possible that differences in CSF batches between ADNI-1 and ADNI-2/GO could be driving the differences in effect size between the two groups. In the present analysis, it is difficult to distinguish batch effects from group differences because we used the first CSF observation for each subject (thus the batches align roughly with ADNI-1 subjects vs. ADNI-2/GO subjects). However, it should be noted that previous work has demonstrated the test-retest reliability of the biomarker measures from CSF in the

ADNI data set [31]. An additional independent sample with a longitudinal follow-up interval comparable with that of ADNI-1 could help clarify whether the cohort differences observed are simply due to longitudinal power or differences due to batch effects, MRI follow-up interval, or sample characteristics.

Our post hoc analyses highlight a possible mechanism of the observed genetic interaction based on alterations in the neuroinflammatory response. It should be noted that these post hoc effects did not survive correction for multiple comparisons. The present project was not powered to look for all possible SNP effects across the entire proteomic panel, and the trend seen with IL-6R should be interpreted conservatively as a hint at a potential mechanism. Future functional work confirming the mechanism of the observed SNP interaction will be necessary to the underlying mechanism.

Future work replicating our findings in an independent sample with MRI, CSF, and genotype data is needed to confirm the observed SNP effect. To avoid possible confounding factors related to population substructure, we chose to restrict all analyses to Caucasian individuals, and thus, our results may not generalize to other ancestral populations. The statistical approach taken in the present manuscript provides a blueprint for future exploratory analyses aimed at identifying genetic modifiers of disease risk using other AD biomarkers such as amyloid load measured using PET and provides some possible targets for future functional analyses.

Acknowledgments

The authors report no conflicts of interest. This research was supported in part by the Vanderbilt NIMH Neurogenomics Training grant (T32 MH65215), the Vanderbilt Medical Scientist Training Program (T32 GM07347), the Recruitment for Genetic Aging Research (P30 AG036445), and the Pharmaceutical Research and Manufacturers of America Foundation Fellowship in Translational Medicine and Therapeutics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data collection and sharing for this project was funded by ADNI (National Institutes of Health grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd; AstraZeneca; Bayer HealthCare; BioClinica, Inc; Biogen Idec, Inc; Bristol-Myers Squibb Company; Eisai, Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; GE Healthcare; Innogenetics, N.V.; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace, Inc; Merck & Co, Inc; Meso Scale Diagnostics, LLC; Novartis

Pharmaceuticals Corporation; Pfizer Inc; Servier; Synarc Inc; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation or the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for NeuroImaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514.

RESEARCH IN CONTEXT

1. Systematic review: The authors performed a comprehensive review of existing work categorizing the relationship between phosphorylated tau (PTau) and brain volume, as well as genetic modifiers of this relationship. Previous research had been somewhat mixed with some studies finding only trend-level associations between cerebrospinal fluid (CSF) tau/PTau and brain volume. No work to date has investigated genetic modifiers of this relationship beyond the *APOE* genotype.
2. Interpretation: Our results further clarify the relationship between CSF PTau and brain volume, identify a novel genetic interaction that explains substantial variance in brain atrophy, and identify a possible mechanism of the observed interaction related to a neuroinflammatory response.
3. Future directions: Although subdividing our data set into ADNI-1 and ADNI-2/GO suggested the interaction was consistent, a replication of this gene-biomarker interaction is warranted. Future functional analyses investigating the relationship between *POT1* and the neuroinflammatory response are also necessary to confirm our suggested mechanism of action.

References

- [1] Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. *Acta Neuropathol* 2011; 121:171–81.
- [2] Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol* 2010;9:119.
- [3] Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol* 2013;12:207–16.
- [4] Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiol Aging* 1997;18:351–7.
- [5] Driscoll I, Troncoso J. Asymptomatic Alzheimers disease: a prodrome or a state of resilience? *Curr Alzheimer Res* 2011;8:330–5.
- [6] Iacono D, O'Brien R, Resnick SM, Zonderman AB, Pletnikova O, Rudow G, et al. Neuronal hypertrophy in asymptomatic Alzheimer disease. *J Neuropathol Exp Neurol* 2008;67:578.
- [7] Codispoti KT, Beason-Held LL, Kraut MA, O'Brien RJ, Rudow G, Pletnikova O, et al. Longitudinal brain activity changes in asymptomatic Alzheimer disease. *Brain Behav* 2012;2:221–30.
- [8] Lampert EJ, Roy Choudhury K, Hostage CA, Petrella JR, Doraiswamy PM, the Alzheimer's Disease Neuroimaging Initiative. Prevalence of Alzheimer's pathologic endophenotypes in asymptomatic and mildly impaired first-degree relatives. *PLoS One* 2013; 8:e60747.
- [9] Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. *Ann Neurol* 2006;59:512–9.
- [10] Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. *Neurobiol Aging* 2008;29:1456–65.
- [11] Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. *Neurology* 2009;73:1193–9.
- [12] Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at *CLU* and *PICALM* associated with Alzheimer's disease. *Nat Genet* 2009;41:1088–93.
- [13] Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at *ABCA7*, *MS4A6A/MS4A4E*, *EPHA1*, *CD33* and *CD2AP* are associated with Alzheimer's disease. *Nat Genet* 2011;43:429–35.
- [14] Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. *PLoS Genet* 2010; 6:e1001101.
- [15] Cruchaga C, Kauwe J, Harari O, Jin SC, Cai Y, Karch CM, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimers disease. *Neuron* 2013;78:256–68. 4–24.
- [16] Kauwe JSK, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, et al. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. *Neurogenetics* 2009;10:13–7.
- [17] Kauwe JSK, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, et al. Fine mapping of genetic variants in *BIN1*, *CLU*, *CR1* and *PICALM* for association with cerebrospinal fluid biomarkers for Alzheimer's disease. *PLoS One* 2011;6:e15918.
- [18] Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, et al. Genome-wide association study of CSF biomarkers Abeta-42, t-tau, and p-tau181p in the ADNI cohort. *Neurology* 2011;76:69–79.
- [19] Thompson PM, Hayashi KM, de Zubicaray GI, Janke AL, Rose SE, Semple J, et al. Mapping hippocampal and ventricular change in Alzheimer disease. *Neuroimage* 2004;22:1754–66.
- [20] Jack CR, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. *Neurology* 2004; 62:591–600.
- [21] Koran MI, Hohman TJ, Meda SA, Thornton-Wells TA. Genetic interactions within inositol-related pathways are associated with longitudinal changes in ventricle size. *J Alzheimers Dis* 2014;38:145–54.
- [22] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; 81:559–75.

- [23] Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. *J Magn Reson Imaging* 2008;27:685–91.
- [24] Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. *Brain* 2009;132:1310–23.
- [25] Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. *Brain* 2006;129:3035–41.
- [26] Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis: I. Segmentation and surface reconstruction. *Neuroimage* 1999;9:179–94.
- [27] Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage* 2006;31:968–80.
- [28] Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis: II: inflation, flattening, and a surface-based coordinate system. *Neuroimage* 1999;9:195–207.
- [29] Fischl B, Sereno MI, Tootell RB, Dale AM. High-resolution intersubject averaging and a coordinate system for the cortical surface. *Hum Brain Mapp* 1999;8:272–84.
- [30] Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. *Neuroimage* 2012;61:1402–18.
- [31] Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. *Acta Neuropathol* 2011;121:597–609.
- [32] Ramanan VK, Risacher SL, Nho K, Kim S, Swaminathan S, Shen L, et al. *APOE* and *BCHE* as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. *Mol Psychiatry* 2013; <http://dx.doi.org/10.1038/mp.2013.19>.
- [33] Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. *Genetics* 2000;155:945–59.
- [34] Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Brain Imaging Behav* 2012;6:1–15.
- [35] Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. *Brain Imaging Behav* 2012;1–11.
- [36] Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. *Brain* 2009;132:1067–77.
- [37] de Souza LC, Chupin M, Lamari F, Jardel C, Leclercq D, Colliot O, et al. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. *Neurobiol Aging* 2012;33:1253–7.
- [38] Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, et al. Decreased cerebrospinal fluid Abeta-42 correlates with brain atrophy in cognitively normal elderly. *Ann Neurol* 2009;65:176–83.
- [39] Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res* 2012;40:D930–4.
- [40] Kondo T, Oue N, Yoshida K, Mitani Y, Naka K, Nakayama H, et al. Expression of *POT1* is associated with tumor stage and telomere length in gastric carcinoma. *Cancer Res* 2004;64:523–9.
- [41] Ning X, Yang S, Wang R, Zhang R, Guo L, Tie J, et al. *POT1* deficiency alters telomere length and telomere-associated gene expression in human gastric cancer cells. *Eur J Cancer Prev* 2010;19:345–51.
- [42] Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D, et al. Telomere shortening in T cells correlates with Alzheimer's disease status. *Neurobiol Aging* 2003;24:77–84.
- [43] Jefferson AL, Massaro JM, Wolf PA, Seshadri S, Au R, Vasan RS, et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. *Neurology* 2007;68:1032–8.
- [44] Calvert PA, Liew TV, Gorenne I, Clarke M, Costopoulos C, Obaid DR, et al. Leukocyte telomere length is associated with high-risk plaques on virtual histology intravascular ultrasound and increased proinflammatory activity. *Arterioscler Thromb Vasc Biol* 2011;31:2157–64.
- [45] Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. *J Clin Endocrinol Metab* 2006;91:439–46.
- [46] Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. *FASEB J* 2001;15:43–58.
- [47] Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, et al. Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's Disease Neuroimaging Initiative database. *Brain* 2008;131:2443–54.
- [48] Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: a study of the ADNI cohort. *Neuroimage* 2010;53:1051.
- [49] Mukherjee S, Kim S, Ramanan VK, Gibbons L, Nho K, Gymour M, et al. Gene-based GWAS and biological pathway analysis of the resilience of executive functioning. *Brain Imaging Behav* 2014;8:110–8.

Appendix

Genotyping

QC and statistical analyses were performed using the PLINK software (version 1.07) [22]. During QC, we excluded SNPs with genotyping efficiency <90%, minor allele frequency <10%, or deviation from Hardy-Weinberg equilibrium ($P < 1 \times 10^{-6}$). This left 515,383 SNPs in ADNI-1 and 605,317 SNPs in ADNI-2/GO. Finally, we merged the two genotyping files for our analyses and again applied filters for genotyping efficiency <90% and minor allele frequency <10%. Subjects were excluded if they had a call rate <98%, if there was a reported versus genetic sex inconsistency, or if relatedness to another sample was established ($PI_HAT > 0.5$).

Quantification of ventricular dilation

The MRI processing pipeline has been described elsewhere [23]. Cortical reconstruction and volumetric segmentation were performed with the FreeSurfer image analysis suite, version 4.3 (<http://surfer.nmr.mgh.harvard.edu/>) [26–30]. FreeSurfer processing in ADNI has been described in detail elsewhere [24]. An early version of the longitudinal image processing framework was used to process the sequential scans [30]. We excluded volumetric data from subjects who did not pass ventricle QC as outlined in the ADNI FreeSurfer processing pipeline from the ADNI MRI core (http://adni.loni.ucla.edu/wp-content/uploads/2010/12/ADNI_UCSF_Freesurfer-Overview-and-QC.pdf). Past work has demonstrated that, when measured longitudinally, the left inferior lateral ventricle shows greater dilation than the right, in both AD patients and controls [19]. For this reason, we chose to focus on the left ventricle to reduce the total number of comparisons, while allowing for maximal power in detecting genetic effects related to progression. Slopes of change in left ventricular volume over time were calculated in SAS 9.3 (SAS Institute Inc) using mixed model regression (PROC MIXED) to leverage the longitudinal data available. In the mixed model regression, time was modeled based on days from baseline for each subject. This was then rescaled so that slopes would represent annual change (days from baseline/365.25). On average, we had four MRI scans for each subject (3.66 for subjects in ADNI-1 and 4.62 for subjects in ADNI-2/ADNIGO).

CSF P τ preprocessing

We compiled a data set across the UPENN1 to UPENN5 data sources available for download on the ADNI site. For the present analyses, we used the first measure of P τ for each subject, given its previous association with neurofibrillary tangle pathology [25]. Two subjects had P τ values greater than three standard deviations beyond the mean levels in both the AD and MCI groups and were excluded from our analyses.

Hierarchical linear regression to identify variance explained

To place our observed SNP interaction effects in the context of known predictors of brain volume, we used hierarchical linear regression to calculate the change in R^2 when adding in the SNP main effect and after adding in the SNP \times P τ interaction term. For this model, we also chose to include the *APOE* genotype as a predictor to determine whether our observed SNP effects explained variance beyond this known major genetic predictor. Although we restricted analyses to Caucasian individuals, we also included population structure covariates in this model (calculated using Structure, <http://pritch.bsd.uchicago.edu/structure.html>) [33] to ensure there was no effect of ancestry contributing to the observed interaction.

Slopes of ventricular volume were again set as the quantitative outcome. Our first block included baseline age, gender, years of education, baseline ICV, baseline diagnostic category, and P τ . Our second block added in the *APOE* genotype (number of $\epsilon 4$ alleles). Our third block added in the population structure eigenvectors. Our fourth block added in the SNP main effect term, and our final block added in the SNP \times P τ interaction term. We report the variance explained by the final block in this model, which is the variance explained by the SNP \times P τ interaction term.

Post hoc cognitive performance analysis

Composite measures of memory and executive function were calculated previously in ADNI and are described elsewhere [34,35]. We performed one cognitive analysis using memory as the outcome (ADNI-MEM) and one analysis using executive function as the outcome (ADNI-EF) to test whether the observed interaction effects were associated with cognitive performance. The outcome measure was either baseline ADNI-EF or baseline ADNI-MEM, and predictors included baseline age, gender, years of education, diagnostic group, *APOE*, P τ , SNP, and the SNP \times P τ interaction term.

Post hoc neuroinflammatory cytokine analysis

Plasma-based proteomic markers have been previously calculated in ADNI and are described elsewhere (http://adni.loni.ucla.edu/wp-content/uploads/2010/11/BC_Plasma_Proteomics_Data_Primer.pdf). For post hoc analyses, we chose to focus on all IL and TNF- α markers that passed QC leaving seven markers for analysis: TNF- α , IL-3, IL-8, IL-13, IL-17, IL-18, and IL-6R. Each of these was a quantitative outcome measure in regression models using the same predictors as the cognitive post hoc analyses. We again corrected for multiple comparisons using the Bonferroni procedure.